AnaCardio AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AnaCardio AB - overview
Established
2017
Location
Stockholm, -, Sweden
Primary Industry
Biotechnology
About
Founded in 2017 and based in Stockholm, Sweden, AnaCardio AB operates as a clinical-stage biopharmaceutical firm that creates medications for treating heart problems. AnaCardio AB engaged in the development of AC01 for the treatment of heart failure that targets the underlying cause of heart failure: impaired contractility, and can be initiated in acute heart failure and transition to chronic oral use. The AC01 drug mimics the peptide and analogously increases contractility ex vivo. In January 2025, AnaCardio AB raised SEK 205 million in series A funding co-led by new investors BB Pureos Bioventures, Novo Holdings, and Sound Bioventures.
Returning investors Flerie Invest, Industrifonden, and individual investors also participated in the round. The company plans the January 2025 funding to support the clinical study and development of its product.
Current Investors
KDventures, Industrifonden, 3B Future Health Fund
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Cardiology
Website
www.anacardio.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
AnaCardio AB - timeline of key events
AnaCardio AB - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (6,205) | (3,191) | (4,312) | (26,669) | (3,180,728) | - | - | - |
| Operating Income (USD) | (6,205) | (3,191) | (4,312) | (26,669) | (3,180,728) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - |
| NET Income (USD) | (6,205) | (3,191) | (4,312) | (26,669) | (3,180,728) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - |
AnaCardio AB - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.